Clinical Trials

Inclusion Criteria:

Both Aims

1. Women with a pathologic diagnosis of OC.
2. Able to provide informed consent.

Aim 1 and 1a:

1. Underwent debulking surgery for OC within the past 42 days, or planning to receive neoadjuvant chemotherapy or chemotherapy only.

Aim 2:

1. Received at least one prior systemic chemotherapy regimen for OC.
2. Developed recurrence or progression of OC during or after at least one course of systemic chemotherapy.
3. Planning to receive additional systemic therapy for OC.  (Patients not planning to receive additional therapy at Mayo Clinic Rochester must be enrolled in IRB protocol 08-005749.)

Exclusion Criteria:

Both Aims:

1. Borderline tumor or non-epithelial histology (germ cell tumor, carcinosarcoma, etc.).
2. Other malignancy within the past five years, other than non-melanoma skin cancers that have been completely resected or cervical carcinoma in situ.

Aim 1 and 1a:

1. Already received systemic chemotherapy for OC prior to study entry. (While the goal is to enroll patients before their first dose of chemotherapy, patients who have received at most three cycles of their first course of chemotherapy may participate.)

Aim 2 

1. Receipt of vaccines or immunotherapy for OC.Aim 2:
   1. Receipt of systemic anti-cancer therapy within 14 days before study blood draw.
   2. Current (within the past 7 days) known or suspected infection.
   3. Absolute neutrophil count (ANC) < 1000
   4. Platelet count < 75,000.